The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application (TM99155751) for the mark LEYNYSO. The application covers a range of pharmaceutical preparations, including cell therapy and immunotherapy products for cancer treatment, as well as T-cell receptors and engineered T-cell receptor therapeutics. It also includes medical services related to immunotherapy, such as harvesting and infusing a patient's white blood cells with engineered T-cell receptor therapeutics.

This filing indicates a potential new market entrant or product launch in the cell therapy and immunotherapy space. While this is a trademark application and not a regulatory approval, it signals commercial intent for these advanced medical treatments. Compliance officers in the pharmaceutical and healthcare sectors should note the scope of the proposed services and products, which may be subject to future FDA or other regulatory oversight upon commercialization.